Overview

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

Status:
Completed

Trial end date:
1995-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of abciximab, an anti-platelet therapy, versus placebo in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty.

Phase:

Phase 3

Details

Lead Sponsor:

Centocor, Inc.

Treatments:

Abciximab
Antibodies, Monoclonal
Immunoglobulin Fab Fragments